All News

2020

August

Media Release / Aug 04, 2020

Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma

Read More

July

Media Release / Jul 29, 2020

Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Media Release / Jul 24, 2020

Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease

Read More
The inflammasome
Story / Jul 24, 2020

Breaking a vicious cycle of inflammation

Novartis researchers aim to quash inflammation to treat chronic disease.

Read More
Media Release / Jul 23, 2020

Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints

Read More
Media Release / Jul 21, 2020

Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

Read More
SARS-CoV-2, the novel coronavirus at the root of the COVID-19 pandemic
Story / Jul 09, 2020

Cancer didn’t stop for COVID-19

Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.

Read More
Media Release / Jul 01, 2020

Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case

Read More

June

Media Release / Jun 29, 2020

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14

Read More
Media Release / Jun 29, 2020

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More